Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis

Previous evidence suggests that the humanized anti-VEGF antibody bevacizumab increases thrombosis risk in glioma patients. Here, we comprehensively assessed the risk of adverse vascular events in adult glioma patients receiving bevacizumab therapy. Systematic searches of MEDLINE, EMBASE, and the Coc...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaoqing, Huang, Rongzhong, Xu, Zhongye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589758/
https://www.ncbi.nlm.nih.gov/pubmed/26423913
http://dx.doi.org/10.1038/srep14698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589758/
https://www.ncbi.nlm.nih.gov/pubmed/26423913
http://dx.doi.org/10.1038/srep14698

Ejemplares similares